COLTRO, GIACOMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.201
EU - Europa 1.029
AS - Asia 281
AF - Africa 5
SA - Sud America 5
Totale 2.521
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.194
RU - Federazione Russa 559
IT - Italia 166
IE - Irlanda 121
HK - Hong Kong 86
CN - Cina 79
SE - Svezia 73
SG - Singapore 71
CH - Svizzera 61
IN - India 26
FI - Finlandia 21
JO - Giordania 16
DE - Germania 11
CA - Canada 7
GB - Regno Unito 6
CI - Costa d'Avorio 5
BR - Brasile 3
FR - Francia 3
AR - Argentina 2
AT - Austria 2
ES - Italia 2
JP - Giappone 2
UA - Ucraina 2
KR - Corea 1
NL - Olanda 1
PL - Polonia 1
Totale 2.521
Salva come PNG Salva come JPEG
Città #
Santa Clara 384
Dublin 121
Ashburn 95
Fairfield 80
Chandler 68
Bern 61
Moscow 60
Hong Kong 56
Singapore 53
Woodbridge 37
Cambridge 36
Seattle 34
Altamura 31
Lawrence 30
Houston 25
Kent 23
Wilmington 23
Mumbai 22
Florence 20
Helsinki 19
Shanghai 19
Buffalo 18
Princeton 18
Beijing 15
Boston 13
New York 12
Washington 12
Ann Arbor 11
Sesto Fiorentino 8
Bremen 7
Milan 6
Pian di Scò 6
West Jordan 6
Yubileyny 6
Abidjan 5
Boardman 5
Cervia 5
Fiesole 5
Los Angeles 5
Medford 5
San Diego 5
Hillsboro 4
Napoli 4
Pune 4
Toronto 4
Hangzhou 3
Romola 3
San Jose 3
Andover 2
Buenos Aires 2
Cagliari 2
Chengdu 2
Cortona 2
Dearborn 2
Fuzhou 2
Hefei 2
Jacksonville 2
Jinhua 2
Maranello 2
Norwalk 2
Paris 2
Pavia 2
Pisa 2
Red Deer 2
Reston 2
Rimini 2
Rome 2
San Giovanni Valdarno 2
Sant'elpidio A Mare 2
Seville 2
Shenzhen 2
Siena 2
São Leopoldo 2
Tokyo 2
Vienna 2
Villa Minozzo 2
Abenberg 1
Arezzo 1
Azzano Decimo 1
Brescia 1
Brugherio 1
Caronno Pertusella 1
Catania 1
Catanzaro 1
Clifton 1
Falkenstein 1
Falls Church 1
Fano 1
Fiumicino 1
Fontebuona 1
Hounslow 1
Jinan 1
Jining 1
Kunming 1
Lappeenranta 1
Leawood 1
Livorno 1
London 1
Lugo di Vicenza 1
Monteriggioni 1
Totale 1.575
Salva come PNG Salva come JPEG
Nome #
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study 127
Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs) 124
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative 121
A life-threatening ruxolitinib discontinuation syndrome 121
Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature 105
Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients 101
Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients 98
RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features 91
Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Adult Patients 82
Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera 77
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis 75
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis 74
Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2V617F Variant Allele Frequency≤ 1% 68
Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms 67
Integration of molecular information in risk assessment of patients with myeloproliferative neoplasms 65
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera 61
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project 60
Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis 60
Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities 60
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis 57
Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients 53
Cutaneous blastic plasmacytoid dendritic cell neoplasm arising in the context of TET2 and ZRSR2 mutated clonal cytopenias of unknown significance, secondary to somatic copy number losses involving CDK2NA/2NB and MTAP 51
The safety of JAK kinase inhibitors for the treatment of myelofibrosis 51
Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment 50
Mutations and thrombosis in essential thrombocythemia 50
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis 49
Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis 49
Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia 48
The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions 47
Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms 46
Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis 45
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis 41
RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis 40
Hematologic Neoplasms Associated with Down Syndrome: Cellular and Molecular Heterogeneity of the Diseases 39
A challenging diagnosis of myeloid/lymphoid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement 39
Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis 37
Response to erythropoiesis‐stimulating agents in patients with WHO‐defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN‐RS‐T) 36
Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms 35
Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients 32
SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates 31
Thrombotic risk correlates with mutational status in true essential thrombocythemia 30
Totale 2.593
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.366
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.366
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020126 0 0 0 0 11 16 23 26 21 10 11 8
2020/2021125 2 8 25 38 4 6 3 10 9 8 9 3
2021/2022110 2 1 3 1 4 5 0 22 14 1 23 34
2022/2023559 34 87 36 23 56 90 69 21 35 15 16 77
2023/2024445 18 25 56 18 39 75 11 79 12 50 43 19
2024/20251.177 57 206 122 318 474 0 0 0 0 0 0 0
Totale 2.593